Lantheus Faces Investor Lawsuits Over Pylarify Product Claims

Lantheus Holdings finds itself at the center of a significant legal challenge as a series of class-action lawsuits allege the company misled investors regarding the commercial prospects of its key product, Pylarify, a prostate cancer imaging agent. The complaints, filed by multiple prominent law firms, accuse the biopharmaceutical firm of securities fraud, creating a critical test for its management and investor relations.

Legal Challenges and Market Impact

The core allegation is that between February and August 2025, Lantheus issued overly optimistic statements about the growth potential and competitive standing of Pylarify. According to the legal filings, these purported misrepresentations are directly linked to severe stock price declines experienced during that period. The lawsuits point to two specific events that triggered investor losses.

In May 2025, the company revised its annual forecast downward following disappointing quarterly results, which precipitated a dramatic 23% single-day drop in its share value. The situation worsened in August when a further profit warning and the revelation of an 8.3% decline in Pylarify revenue caused the equity to plunge by nearly 29%.

Shifting Analyst Sentiment

The unfolding legal and financial situation has prompted a reassessment among market observers. Several analyst firms have revised their projections for Lantheus. For instance, B. Riley significantly lowered its third-quarter earnings per share (EPS) estimate from $1.36 to $1.02. In a similar move, TD Cowen reduced its price target from $95 to $80. While both firms have, for now, maintained their “buy” recommendations, the growing uncertainty is evident.

Should investors sell immediately? Or is it worth buying Lantheus?

Despite the current pressures, Lantheus continues to pursue strategic initiatives aimed at long-term stability. The acquisitions of Evergreen Theragnostics and Life Molecular Imaging are part of a plan to diversify its business and strengthen its research and development pipeline. Company leadership is also pinning hopes on a new formulation of Pylarify, currently under review by the FDA, which has the potential to significantly boost production capacity.

A Pivotal Quarter Ahead

All attention is now focused on the upcoming third-quarter financial report, scheduled for release in November. The sales figures for Pylarify will be scrutinized as a key indicator of the company’s health. The stock, which has lost more than half its value since the start of the year and is currently trading near its 52-week low of €42.70, remains under the dual pressure of operational challenges and legal proceedings.

The November results will provide a crucial signal as to whether Lantheus can begin to restore market confidence or if it faces a protracted legal battle that could lead to further volatility for its shareholders.